These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 25483082)

  • 21. Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity.
    Skorta I; Oren M; Markwardt C; Gutekunst M; Aulitzky WE; van der Kuip H
    Cancer Res; 2009 Dec; 69(24):9337-45. PubMed ID: 19934315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. UV Differentially Induces Oxidative Stress, DNA Damage and Apoptosis in BCR-ABL1-Positive Cells Sensitive and Resistant to Imatinib.
    Synowiec E; Hoser G; Wojcik K; Pawlowska E; Skorski T; Błasiak J
    Int J Mol Sci; 2015 Aug; 16(8):18111-28. PubMed ID: 26251899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
    Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
    Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
    Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
    Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of BCR-ABL1 oncogene relative to ABL1 gene changes overtime in chronic myeloid leukemia.
    Gupta M; Milani L; Hermansson M; Simonsson B; Markevärn B; Syvänen AC; Barbany G
    Biochem Biophys Res Commun; 2008 Feb; 366(3):848-51. PubMed ID: 18082628
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.
    Andreu EJ; Lledó E; Poch E; Ivorra C; Albero MP; Martínez-Climent JA; Montiel-Duarte C; Rifón J; Pérez-Calvo J; Arbona C; Prósper F; Pérez-Roger I
    Cancer Res; 2005 Apr; 65(8):3264-72. PubMed ID: 15833859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Translational control of cytochrome c by RNA-binding proteins TIA-1 and HuR.
    Kawai T; Lal A; Yang X; Galban S; Mazan-Mamczarz K; Gorospe M
    Mol Cell Biol; 2006 Apr; 26(8):3295-307. PubMed ID: 16581801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of oncogenic kinase Bcr-Abl impairs mitotic checkpoint and promotes aberrant divisions and resistance to microtubule-targeting agents.
    Wolanin K; Magalska A; Kusio-Kobialka M; Podszywalow-Bartnicka P; Vejda S; McKenna SL; Mosieniak G; Sikora E; Piwocka K
    Mol Cancer Ther; 2010 May; 9(5):1328-38. PubMed ID: 20442314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional antagonism between RNA binding proteins HuR and CUGBP2 determines the fate of COX-2 mRNA translation.
    Sureban SM; Murmu N; Rodriguez P; May R; Maheshwari R; Dieckgraefe BK; Houchen CW; Anant S
    Gastroenterology; 2007 Mar; 132(3):1055-65. PubMed ID: 17383427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of apoptosis in imatinib sensitive and resistant chronic myeloid leukemia cells by efficient disruption of bcr-abl oncogene with zinc finger nucleases.
    Huang N; Huang Z; Gao M; Luo Z; Zhou F; Liu L; Xiao Q; Wang X; Feng W
    J Exp Clin Cancer Res; 2018 Mar; 37(1):62. PubMed ID: 29554925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients.
    Arun AK; Senthamizhselvi A; Mani S; Vinodhini K; Janet NB; Lakshmi KM; Abraham A; George B; Srivastava A; Srivastava VM; Mathews V; Balasubramanian P
    Int J Lab Hematol; 2017 Jun; 39(3):235-242. PubMed ID: 28035733
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Downregulation of γ-catenin inhibits CML cell growth and potentiates the response of CML cells to imatinib through β-catenin inhibition.
    Niu CC; Zhao C; Yang ZD; Zhang XL; Wu WR; Pan J; Zhao C; Li ZQ; Ding W; Yang Z; Si WK
    Int J Mol Med; 2013 Feb; 31(2):453-8. PubMed ID: 23233089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.
    Mukherjee K; Sha X; Magimaidas A; Maifrede S; Skorski T; Bhatia R; Hoffman B; Liebermann DA
    Oncotarget; 2017 Feb; 8(7):10809-10821. PubMed ID: 28086219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of isoprenylcysteine carboxylmethyltransferase augments BCR-ABL1 tyrosine kinase inhibition-induced apoptosis in chronic myeloid leukemia.
    Sun WT; Xiang W; Ng BL; Asari K; Bunte RM; Casey PJ; Wang M; Chuah C
    Exp Hematol; 2016 Mar; 44(3):189-93.e2. PubMed ID: 26706195
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNA Repair--A Double-Edged Sword in the Genomic Stability of Cancer Cells--The Case of Chronic Myeloid Leukemia.
    Pawlowska E; Blasiak J
    Int J Mol Sci; 2015 Nov; 16(11):27535-49. PubMed ID: 26593906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BCR-ABL1 kinase domain mutation analysis in an Irish cohort of chronic myeloid leukemia patients.
    McCarron SL; O'Connor LM; Langabeer SE; Conneally E
    Genet Test Mol Biomarkers; 2013 Feb; 17(2):170-3. PubMed ID: 23289634
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MKP-1 mRNA stabilization and translational control by RNA-binding proteins HuR and NF90.
    Kuwano Y; Kim HH; Abdelmohsen K; Pullmann R; Martindale JL; Yang X; Gorospe M
    Mol Cell Biol; 2008 Jul; 28(14):4562-75. PubMed ID: 18490444
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.
    Lin TY; Chen KC; Liu HJ; Liu AJ; Wang KL; Shih CM
    PLoS One; 2016; 11(5):e0156260. PubMed ID: 27228340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of human antigen R, an RNA-binding protein, in mediating the stabilization of toll-like receptor 4 mRNA induced by endotoxin: a novel mechanism involved in vascular inflammation.
    Lin FY; Chen YH; Lin YW; Tsai JS; Chen JW; Wang HJ; Chen YL; Li CY; Lin SJ
    Arterioscler Thromb Vasc Biol; 2006 Dec; 26(12):2622-9. PubMed ID: 16990552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients.
    De Carvalho DD; Binato R; Pereira WO; Leroy JM; Colassanti MD; Proto-Siqueira R; Bueno-Da-Silva AE; Zago MA; Zanichelli MA; Abdelhay E; Castro FA; Jacysyn JF; Amarante-Mendes GP
    Oncogene; 2011 Jan; 30(2):223-33. PubMed ID: 20838376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.